• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2014-2018 年美国医疗中心儿童血流感染病原菌的分布及药敏分析:多重耐药菌的治疗选择

Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteria.

机构信息

JMI Laboratories, North Liberty, Iowa, USA.

JMI Laboratories, North Liberty, Iowa, USA.

出版信息

Diagn Microbiol Infect Dis. 2020 Oct;98(2):115108. doi: 10.1016/j.diagmicrobio.2020.115108. Epub 2020 Jun 13.

DOI:10.1016/j.diagmicrobio.2020.115108
PMID:32640386
Abstract

Studies evaluating large series of pediatric patients with bloodstream infections (BSIs) are scarce. We evaluated the frequency and antimicrobial susceptibility of organisms isolated from pediatric patients with BSI and therapeutic options for BSI caused by multidrug-resistant (MDR) organisms. A total of 2423 organisms were consecutively collected from 33 US medical centers between 2014 and 2018, and susceptibility was tested by reference broth microdilution methods. Isolates with an extended-spectrum β-lactamase phenotype were screened for β-lactamase genes. Overall, 40.2% of organisms were Gram-negative bacteria, 57.0% Gram-positives, and 2.8% Candida spp. The 5 most common organisms were Staphylococcus aureus (26.0%), Escherichia coli (13.0%), coagulase-negative staphylococci (8.3%), Enterococcus faecalis (7.1%), and Klebsiella pneumoniae (6.9%). Among S. aureus, 26.0% were oxacillin-resistant and 99.8% were susceptible to ceftaroline (MIC, 0.25/0.5 mg/L). Enterobacterales and Pseudomonas aeruginosa isolates combined represented >85% of Gram-negative bacteria, and all isolates (100.0%) were susceptible to ceftazidime-avibactam.

摘要

评估小儿血流感染(BSI)大系列患者的研究很少。我们评估了从小儿 BSI 患者中分离的病原体的频率和药敏性,以及耐多药(MDR)病原体引起的 BSI 的治疗选择。2014 年至 2018 年间,我们从美国 33 家医疗中心连续采集了 2423 株病原体,并通过参考肉汤微量稀释法进行了药敏性测试。对具有扩展谱β-内酰胺酶表型的分离物进行了β-内酰胺酶基因筛查。总的来说,40.2%的病原体为革兰氏阴性菌,57.0%为革兰氏阳性菌,2.8%为念珠菌属。最常见的 5 种病原体为金黄色葡萄球菌(26.0%)、大肠杆菌(13.0%)、凝固酶阴性葡萄球菌(8.3%)、粪肠球菌(7.1%)和肺炎克雷伯菌(6.9%)。金黄色葡萄球菌中,26.0%为耐苯唑西林,99.8%对头孢他啶-克拉维酸敏感(MIC,0.25/0.5mg/L)。肠杆菌科和铜绿假单胞菌的分离物联合占革兰氏阴性菌的>85%,所有分离物(100.0%)均对头孢他啶-阿维巴坦敏感。

相似文献

1
Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteria.2014-2018 年美国医疗中心儿童血流感染病原菌的分布及药敏分析:多重耐药菌的治疗选择
Diagn Microbiol Infect Dis. 2020 Oct;98(2):115108. doi: 10.1016/j.diagmicrobio.2020.115108. Epub 2020 Jun 13.
2
Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.2011年至2015年在美国医疗中心住院治疗肺炎的患者中分离出的革兰氏阴性菌对头孢他啶-阿维巴坦的抗菌活性
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02083-16. Print 2017 Apr.
3
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).头孢他啶-阿维巴坦的抗菌活性和谱在测试儿科患者的革兰氏阴性菌时的结果:来自 INFORM 监测计划(美国,2011-2015 年)。
Pediatr Infect Dis J. 2018 Jun;37(6):549-554. doi: 10.1097/INF.0000000000001859.
4
In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).亚太地区 INFORM 项目(2015-2017 年)收集的革兰氏阴性细菌分离株的头孢他啶-阿维巴坦和对照药物的体外活性。
Ann Clin Microbiol Antimicrob. 2020 Apr 1;19(1):14. doi: 10.1186/s12941-020-00355-1.
5
Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).美国医疗中心 ICU 住院肺炎患者分离的革兰氏阴性菌的频率和抗菌药物敏感性(2015-17 年)。
J Antimicrob Chemother. 2018 Nov 1;73(11):3053-3059. doi: 10.1093/jac/dky279.
6
Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).头孢洛林针对儿科患者分离出的细菌的活性测试:来自美国全球抗菌药物耐药性评估与评价项目(2011 - 2012年)的结果。
Pediatr Infect Dis J. 2014 Aug;33(8):837-42. doi: 10.1097/INF.0000000000000307.
7
Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).2013 - 2014年头孢他啶-阿维巴坦及对照药物对癌症患者感染病原菌的抗菌活性
Diagn Microbiol Infect Dis. 2017 Mar;87(3):261-265. doi: 10.1016/j.diagmicrobio.2016.11.019. Epub 2016 Nov 29.
8
Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.2012年至2014年在INFORM全球监测研究中收集的多药耐药克雷伯菌属对头孢他啶-阿维巴坦的体外活性评估
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4677-83. doi: 10.1128/AAC.02841-15. Print 2016 Aug.
9
Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).检测美国医疗中心从急性细菌性皮肤和皮肤结构感染中分离出的细菌对头孢洛林联合阿维巴坦的抗菌活性(2010-2012 年)。
Diagn Microbiol Infect Dis. 2014 Apr;78(4):449-56. doi: 10.1016/j.diagmicrobio.2014.01.003. Epub 2014 Jan 14.
10
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).比较头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对 2017-2018 年美国医疗中心住院肺炎患者分离的革兰氏阴性菌的体外活性。
Diagn Microbiol Infect Dis. 2020 Mar;96(3):114833. doi: 10.1016/j.diagmicrobio.2019.05.005. Epub 2019 May 10.

引用本文的文献

1
Vancomycin Area Under the Curve to Minimum Inhibitory Concentration Ratio for Treatment Effectiveness in Pediatric and Neonatal Staphylococcal Infections: A Systematic Review.万古霉素曲线下面积与最低抑菌浓度比值对儿童及新生儿葡萄球菌感染治疗效果的影响:一项系统评价
J Pediatr Pharmacol Ther. 2025 Feb;30(1):52-64. doi: 10.5863/1551-6776-30.1.52. Epub 2025 Feb 10.
2
Engineering antibacterial bioceramics: Design principles and mechanisms of action.工程抗菌生物陶瓷:设计原理与作用机制
Mater Today Bio. 2024 Apr 27;26:101069. doi: 10.1016/j.mtbio.2024.101069. eCollection 2024 Jun.
3
Antimicrobial Susceptibility Among Gram-Negative Isolates in Pediatric Patients in Latin America, Africa-Middle East, and Asia From 2016-2020 Compared to 2011-2015: Results From the ATLAS Surveillance Study.
2016-2020 年拉丁美洲、非洲-中东和亚洲儿科患者革兰氏阴性分离株的抗菌药物敏感性与 2011-2015 年相比:来自 ATLAS 监测研究的结果。
J Pediatric Infect Dis Soc. 2023 Aug 31;12(8):459-470. doi: 10.1093/jpids/piad055.
4
Proteogenomic analysis of Serratia marcescens using computational subtractive genomics approach.利用计算减基因组学方法对粘质沙雷氏菌进行蛋白质基因组分析。
PLoS One. 2023 Apr 10;18(4):e0283993. doi: 10.1371/journal.pone.0283993. eCollection 2023.
5
Trends of Antimicrobial Susceptibility in Clinically Significant Coagulase-Negative Staphylococci Isolated from Cerebrospinal Fluid Cultures in Neurosurgical Adults: a Nine-Year Analysis.神经外科成人患者脑脊液培养中凝固酶阴性葡萄球菌的临床重要性及抗菌药物敏感性趋势:一项九年分析。
Microbiol Spectr. 2022 Feb 23;10(1):e0146221. doi: 10.1128/spectrum.01462-21. Epub 2022 Feb 9.
6
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.3 个月及以上儿科患者头孢他啶-阿维巴坦的群体药代动力学建模及药效学目标达标概率。
Clin Pharmacol Ther. 2022 Mar;111(3):635-645. doi: 10.1002/cpt.2460. Epub 2021 Nov 22.
7
Ceftazidime-avibactam: are we safe from class A carbapenemase producers' infections?头孢他啶-阿维巴坦:我们能免受 A 类碳青霉烯酶产生菌感染吗?
Folia Microbiol (Praha). 2021 Dec;66(6):879-896. doi: 10.1007/s12223-021-00918-5. Epub 2021 Sep 9.
8
Antibiotic Use Among Hospitalized Children and Neonates in China: Results From Quarterly Point Prevalence Surveys in 2019.中国住院儿童和新生儿的抗生素使用情况:2019年季度现患率调查结果
Front Pharmacol. 2021 Mar 29;12:601561. doi: 10.3389/fphar.2021.601561. eCollection 2021.
9
Sepsis-A Retrospective Cohort Study of Bloodstream Infections.脓毒症——血流感染的回顾性队列研究
Antibiotics (Basel). 2020 Nov 28;9(12):851. doi: 10.3390/antibiotics9120851.